Pair page
BPC-157 Fragment with KPV
Mechanism-tag overlap and published literature for BPC-157 Fragment and KPV, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
derivative-of-bpc-157tissue-repair
alpha-msh-c-terminal-anti-inflammatory-tripeptide
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 Fragment and KPV have published these mechanism-level observations. Not a co-administration recommendation.
Anti-inflammatory tripeptide from α-MSH. Combined for inflammation-dominant cases. Mechanistically distinct from BPC-157 family.
Quick facts
BPC-157 Fragment
KPV
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 Fragment | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (Parent BPC-157 systematic review — does not address fragment-specific evidence; included as… PMID 40756949 | systematic review |
| — | BPC-157 Fragment | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. (Parent peptide trial — no fragment-specific trial registered.) | human trial |
| 2025 | BPC-157 Fragment | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. (Parent peptide human pilot — does not apply to fragment.) PMID 40131143 | human pilot |
| 2024 | BPC-157 Fragment | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 Fragment | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Parent BPC-157 toxicology — no LD1 in mice/rats/rabbits/dogs.) | preclinical, in vivo |
| — | BPC-157 Fragment | Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. (Clarifies BPC-157 nomenclature as… | preclinical, in vivo |
| 2025 | BPC-157 Fragment | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. (Parent peptide; raises evidence-quality concerns applicable to fragment by extension.) PMID 40789979 | review |
| 2024 | BPC-157 Fragment | Sikiric P, Sever M, Krezic I et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract, significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organ protection. Inflammopharmacology.… | review |
| 2026 | BPC-157 Fragment | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (BPC-157 family banned under S0; fragment plausibly included by analogy.) | regulatory / registry |
| 2025 | BPC-157 Fragment | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (BPC-157 fragment shorter sequences are not specifically listed; parent BPC-157 is Category 2.) | regulatory / registry |
| — | BPC-157 Fragment | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. (Applies to parent and by extension to fragment.) | regulatory / registry |
| 2025 | BPC-157 Fragment | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. (Parent peptide; reviews structural features including the GE-PPP-GK mot… PMID 40005999 | research article |
| 2016 | KPV | Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. | preclinical, in vivo |
| 2014 | KPV | Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289-1300.e1-19. | preclinical, in vivo |
| 2010 | KPV | Kannengiesser K, Lügering A, Maaser C, Domschke W, Luger TA, Kucharzik T. Treatment of murine colitis with the tripeptide KPV-review of recent findings. Falk Symp. 2010. | preclinical, in vivo |
| 2008 | KPV | Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 180… PMID 18092346 | preclinical, in vivo |
| 2008 | KPV | Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2… PMID 18612027 | preclinical, in vivo |
| 2013 | KPV | Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Préat V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440(1):3-12. PMID: 22939963. PMID 22939963 | research article |
| 2009 | KPV | Capsoni F, Ongari AM, Reali E, Catania A. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther. 2009;11(5):R151. PMID: 19814815. PMID 19814815 | research article |
| 2008 | KPV | Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177. PMID 18061177 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 Fragment and KPV been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 Fragment and KPV. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 Fragment and KPV share?
BPC-157 Fragment and KPV do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 Fragment and KPV?
BPC-157 Fragment: Research-only. KPV: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 Fragment and KPV?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 Fragment profile and the KPV profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026